Enhancing therapeutic decision making when options abound: Toxicities matter

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 1990-1993

  Kuderer, Nicole M ^a   Wolff, Antonio C ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL DECISION MAKING; DOSE DENSIFICATION; DRUG TOXICITY; EDITORIAL; HOSPITALIZATION; HUMAN; LYMPHOMA; NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HOSPITALIZATION; HUMANS;

EID: 84905842883     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.1903     Document Type: Editorial

References (53)

1. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998 (Pubitemid 28135593)
2. Theriault RL, Carlson RW, Allred C, et al: Breast cancer, version 3.2013: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:753-761, 2013
3. Djulbegovic B, Hozo I, Schwartz A, et al: Acceptable regret in medical decision making. Med Hypotheses 53:253-259, 1999 (Pubitemid 29465503)
4. Khorana AA, Francis CW, Culakova E, et al: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634, 2007 (Pubitemid 46680709)
5. Sivendran S, Latif A, McBride RB, et al: Adverse event reporting in cancer clinical trial publications. J Clin Oncol 32:83-89, 2014
6. Pakhomov SV, Jacobsen SJ, Chute CG, et al: Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care 14:530-539, 2008
7. Fromme EK, Eilers KM, Mori M, et al: How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 22:3485-3490, 2004 (Pubitemid 41103654)
8. Atkinson TM, Li Y, Coffey CW, et al: Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159-1164, 2012
9. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
10. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006 (Pubitemid 46623169)
11. Hamilton EP, Topping JM, Marcom PK, et al: Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/ cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer. J Clin Oncol 31:67s, 2013 (suppl; abstr 1076)
12. Lakhanpal R, Stuart-Harris R, Chan A, et al: A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer. J Clin Oncol 31:68s, 2013 (suppl; abstr 1079)
13. Culakova E, Thota R, Poniewierski MS: Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study. Cancer Med 3:434-444, 2014
14. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006 (Pubitemid 44288785)
15. Rugo HS, Barry WT, Moreno-Aspitia A: CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30:49s, 2012 (suppl; abstr CRA1002)
16. Dale DC, McCarter GC, Crawford J, et al: Myelotoxicity and dose intensity of chemotherapy: Reporting practices from randomized clinical trials. J Natl Compr Canc Netw 1:440-454, 2003
17. Barcenas CH, Niu J, Zhang N, et al: Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 32:2010-2017, 2014
18. Hansen LG, Chang S: White paper: Health research data for the real world. The Thomson Reuters MarketScan Databases, Thomson Reuters, 2011, p 32
19. Extermann M, Boler I, Reich RR, et al: Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377-3386, 2012
20. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
21. Lyman GH, Kuderer NM, Crawford J, et al: Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917-1927, 2011
22. Armstrong K: Methods in comparative effectiveness research. J Clin Oncol 30:4208-4214, 2012
23. Hudis CA, Citron ML, Muss H, et al: Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? J Clin Oncol 30:3148-3149; author reply 3149-3150, 2012
24. Flowers CR, Seidenfeld J, Bow EJ, et al: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794-810, 2013
25. Chevallier B, Chollet P, Merrouche Y, et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564-1571, 1995
26. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
27. Osby E, Hagberg H, Kvaløy S, et al: CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood 101:3840-3848, 2003 (Pubitemid 36857855)
28. Timmer-Bonte JN, de Boo TM, Smit HJ, et al: Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J Clin Oncol 23:7974-7984, 2005 (Pubitemid 46657398)
29. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993 (Pubitemid 23025731)
30. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178-1184, 2005 (Pubitemid 46202274)
31. Fosså SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716-724, 1998
32. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25:3158-3167, 2007 (Pubitemid 47218066)
33. Rajan SS, Lyman GH, Carpenter WR, et al: Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Res Treat 127:511-520, 2011
34. Rajan SS, Lyman GH, Stearns SC, et al: Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy. Med Care 49:649-657, 2011
35. Rajan SS, Stearns SC, Lyman GH, et al: Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat 130:255-266, 2011
36. Hurwitz HI, Lyman GH: Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: Is there a common theme? J Clin Oncol 30:580-581, 2012
37. Meyerhardt JA, Li L, Sanoff HK, et al: Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30:608-615, 2012
38. Sugarman S, Wasserheit C, Hodgman E, et al: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat 115:609-612, 2009
39. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
40. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006 (Pubitemid 43673249)
41. Du XL, Osborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642, 2002 (Pubitemid 36025279)
42. Hershman DL, Lacchetti C, Dworkin RH, et al: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol [epub ahead of print on April 14, 2014]
43. Benet LZ: Review and critique of the Institute of Medicine report "The Future of Drug Safety". Clin Pharmacol Ther 81:158-161, 2007
44. Baciu A, Stratton K, Burke SP (eds): The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press, Washington, DC, 2006. http://www.iom.edu/Reports/2006/The-Future-of-Drug-Safety-Promoting- and-Protecting-the-Health-of-the-Public.aspx
45. Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869, 2010
46. Simonds NI, Khoury MJ, Schully SD, et al: Comparative effectiveness research in cancer genomics and precision medicine: Current landscape and future prospects. J Natl Cancer Inst 105:929-936, 2013
47. Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: A common bond. J Clin Oncol 30:4233-4242, 2012
48. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907, 2008
49. Wu AW, Kharrazi H, Boulware LE, et al: Measure once, cut twice: Adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol 66:S12-S20, 2013
50. Pietanza MC, Basch EM, Lash A, et al: Harnessing technology to improve clinical trials: Study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. J Clin Oncol 31:2004-2009, 2013
51. Jensen RE, Snyder CF, Abernethy AP, et al: Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract [epub ahead of print on December 3, 2013]
52. Hyman DM, Eaton AA, Gounder MM, et al: Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol 32:519-526, 2014
53. Fleming NS, Culler SD, McCorkle R, et al: The financial and nonfinancial costs of implementing electronic health records in primary care practices. Health Aff (Millwood) 30:481-489, 2011